With new therapies that promise to slow Alzheimer’s disease, researchers race to reform how patients are diagnosed

Under new draft guidelines for the diagnosis of Alzheimer’s Disease, unveiled on Sunday at a large international gathering of experts, memory tests would take a backseat to biomarkers—proteins and other signals that can be detected in blood, spinal fluid, and on brain scans—that are telltale signs of the disease process unfolding in the brain.